Further, inhibition of Aurora A and Aurora B is an attractive anticancer approach for a variety of cancers, including solid tumors and hematological malignancies (Gavriilidis, Giakoustidis & Giakoustidis, 2015; Ikezoe et al., 2007; Rodrigues Alves et al., 2016). Here, AURKB is linked to hematologic disorder.